Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection

被引:21
作者
Wranke, Anika [1 ]
Heidrich, Benjamin [1 ]
Deterding, Katja [1 ]
Hupa-Breier, Katharina Luise [1 ]
Kirschner, Janina [1 ]
Bremer, Birgit [1 ]
Cornberg, Markus [1 ,2 ,3 ]
Wedemeyer, Heiner [1 ,2 ,3 ,4 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] German Ctr Infect Res DZIF, Partner Sites Hannover Braunschweig, Braunschweig, Germany
[3] D Solve Consortium, Hannover, Germany
[4] Excellence Cluster Resist, Hannover, Germany
关键词
Hepatitis delta; Hepatitis B; Therapy; Hepatocellular carcinoma; Liver decompensation; Cirrhosis; Clinical longterm outcome; HBeAg; Nucleos(t)ide analogs; Pegylated interferon alpha; CHRONIC DELTA-HEPATITIS; INTERFERON; VIRUS;
D O I
10.1007/s12072-023-10575-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims Hepatitis D virus (HDV) infection causes the most severe form of chronic viral hepatitis. However, it is still unclear to what extent the underlying cirrhosis may contribute to disease progression. The aim of this study was to compare the long-term outcome of HDV infection with HBV monoinfection in a single-center cohort of both non-cirrhotic and cirrhotic patients.Method We retrospectively studied 175 patients with chronic hepatitis D (CHD) who were followed for at least 6 months (median of 6.3 (0.6-23.6) years). In addition, we selected 175 patients with HBV monoinfection (CHB) who were matched for gender, age, region of origin, HBeAg status, and bilirubin. Liver-related clinical end points were defined as hepatic decompensation (ascites, encephalopathy, variceal bleeding), liver transplantation, HCC, or liver-related death.Results Clinical complications developed earlier (4.6 vs. 6.2 years) and more frequently (35.4% vs. 12.6%, p < 0.01) in CHD patients. In a multivariate Cox regression, HDV infection was independently associated with the development of end points (p < 0.01; HR: 3.0; 95% CI 1.4-6.4). However, in cirrhotic patients there were no significant differences between HBV and HDV in the development of end points. Besides, CHB patients with cirrhosis developed more frequently HCC (35.5%) than CHD patients with cirrhosis (18.5%).Conclusion Our results confirmed that HDV leads to a faster progression to cirrhosis compared to HBV. However, once cirrhosis is present, not HDV but the underlying cirrhosis is the dominate intrinsic risk factor for the development of liver-related end points and for the progression to HCC.
引用
收藏
页码:1359 / 1367
页数:9
相关论文
共 25 条
[1]   Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies [J].
Alfaiate, Dulce ;
Clement, Sophie ;
Gomes, Diana ;
Goossens, Nicolas ;
Negro, Francesco .
JOURNAL OF HEPATOLOGY, 2020, 73 (03) :533-539
[2]   High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort [J].
Bockmann, Jan-Hendrik ;
Grube, Marcel ;
Hamed, Vanessa ;
von Felden, Johann ;
Landahl, Johanna ;
Wehmeyer, Malte ;
Giersch, Katja ;
Hall, Michaela T. ;
Murray, John M. ;
Dandri, Maura ;
Lueth, Stefan ;
Lohse, Ansgar W. ;
Luetgehetmann, Marc ;
Schulze Zur Wiesch, Julian .
BMC GASTROENTEROLOGY, 2020, 20 (01)
[3]   Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir [J].
Brancaccio, Giuseppina ;
Fasano, Massimo ;
Grossi, Adriano ;
Santantonio, Teresa Antonia ;
Gaeta, Giovanni B. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (08) :1071-1076
[4]   Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study [J].
Buti, M. ;
Homs, M. ;
Rodriguez-Frias, F. ;
Funalleras, G. ;
Jardi, R. ;
Sauleda, S. ;
Tabernero, D. ;
Schaper, M. ;
Esteban, R. .
JOURNAL OF VIRAL HEPATITIS, 2011, 18 (06) :434-442
[5]  
Cornberg M, 2020, HEPATOLOGY, V71, P1070, DOI [10.1002/hep.31030, 10.1016/j.jhep.2019.11.003]
[6]   Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection [J].
Da, Ben L. ;
Surana, Pallavi ;
Takyar, Varun ;
Kleiner, David E. ;
Heller, Theo ;
Koh, Christopher .
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (04) :428-436
[7]   Long-term benefit of interferon a therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis [J].
Farci, P ;
Roskams, T ;
Chessa, L ;
Peddis, G ;
Mazzoleni, AP ;
Scioscia, R ;
Serra, G ;
Lai, ME ;
Loy, M ;
Caruso, L ;
Desmet, V ;
Purcell, RH ;
Balestrieri, A .
GASTROENTEROLOGY, 2004, 126 (07) :1740-1749
[8]   Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B [J].
Fattovich, G ;
Giustina, G ;
Christensen, E ;
Pantalena, M ;
Zagni, I ;
Realdi, G ;
Schalm, SW .
GUT, 2000, 46 (03) :420-426
[9]   Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies [J].
Kamal, Habiba ;
Fornes, Romina ;
Simin, Johanna ;
Stal, Per ;
Duberg, Ann-Sofi ;
Brusselaers, Nele ;
Aleman, Soo .
JOURNAL OF VIRAL HEPATITIS, 2021, 28 (10) :1431-1442
[10]   Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes [J].
Kamal, Habiba ;
Westman, Gabriel ;
Falconer, Karolin ;
Duberg, Ann-Sofi ;
Weiland, Ola ;
Haverinen, Susanna ;
Wejstal, Rune ;
Carlsson, Tony ;
Kampmann, Christian ;
Larsson, Simon B. ;
Bjorkman, Per ;
Nystedt, Anders ;
Cardell, Kristina ;
Svensson, Stefan ;
Stenmark, Stephan ;
Wedemeyer, Heiner ;
Aleman, Soo .
HEPATOLOGY, 2020, 72 (04) :1177-1190